...Ryo Matsuura; Kent Doi; Yohei Komaru; Yoshihisa Miyamoto; Teruhiko Yoshida; Takuya Isegawa; Kohei Yoshimoto; Tetsushi Yamashita; Eisei Noiri; Masaomi Nangaku Backgrounds/Objectives: Elevated erythropoietin (EPO) is observed in human acute kidney injury (AKI). Whether blood EPO level is associated...

...Imari Mimura; Tetsuhiro Tanaka; Masaomi Nangaku Renal anemia is caused by the deficiency of endogenous erythropoietin (Epo) due to renal dysfunction. We think that it is possible to slow the progression of chronic kidney disease (CKD) in case we initiate Epo early in pre-dialysis patients...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Iron Renal Anemia Chronic kidney disease Dialysis Hemodialysis Kidney Erythropoietin Cardiovascular risk Infection...

...Juan J. Díez; Pedro Iglesias; Julia Sastre; Javier Méndez; Rafael Selgas; Antonio Gómez-Pan Correction of anemia with recombinant human erythropoietin (rhEPO) in patients with end-stage renal disease has been associated with improvement of several abnormalities in hypothalamo-hypophyseal functions...

... of membranoproliferative glomerulonephritis, and the proteinuria was resistant to steroid therapy. Iron deficiency, bleeding and other causes of anemia were ruled out, however, her serum erythropoietin level was inappropriately low. The anemia was rapidly corrected by administration of recombinant human erythropoietin...

...; baseline vs. 2 vs. 4 h, respectively). Our data suggest that the absorption of both ferrous sulfate and ferric polysaccharide complex is poor in patients on CAPD. Iron Niferex® Erythropoietin Anemia Continuous ambulatory peritoneal dialysis © 1996 S. Karger AG, Basel 1996 Copyright / Drug...

...Juan J. Díez; Pedro Iglesias; María A. Bajo; Fernando de Alvaro; Rafael Selgas Long-term therapy with recombinant human erythropoietin (rhEPO) in uremic male patients undergoing hemodialysis has been followed by an increase in plasma levels of testosterone and a decrease in baseline levels...

...Satoru Kuriyam; Haruo Tomonari; Hiroaki Yoshida; Takao Hashimoto; Yoshindo Kawaguchi; Osamu Sakai Therapy with human recombinant erythropoietin (EPO) has been accepted as effective for renal anemia in dialysis patients. However, studies in rats have shown that correcting anemia with EPO may affect...

...Onyekachi Ifudu; Mohammed Dawood; Eli A. Friedman Anemia in chronic renal failure is predominantly caused by diminished erythropoietin synthesis by diseased kidneys. While iron deficiency is often stated as a cause of anemia in chronic renal failure prior to end-stage renal disease, its relative...

... The mechanism of erythropoietin-induced hypertension in dialysis patients is unclear. Intracellular calcium ([Ca 2+ ] i ) may be altered in both hypertension and uraemia, and the effects of both uraemia and r-HuEPO on vascular smooth muscle [Ca 2+ ] i and blood pressure (BP) in Wistar-Kyoto (WKY...

...S. Inomata; M. Itoh; H. Imai; T. Sato Erythropoietin (EPO) is reported to be mainly produced by renal peritubular interstitial cells. Serum levels of EPO may provide new information on the tubulointerstitial lesions in patients with diabetic nephropathy. We determined EPO, hemoglobin (Hb), and Hb...

... Hematocrit increase with recombinant erythropoietin (rEPO) has been associated with increased progression of renal insufficiency in experimental models of renal mass reduction. The aim of the present study was to assess the effects of therapy with rEPO and various antihypertensives...

... Skeletal muscle metabolism during exercise was compared in 5 patients with end-stage renal disease (ESRD) and 8 healthy controls, using a noninvasive technique, 31 P magnetic resonance spectroscopy (MRS). After 3 months of anaemia correction with recombinant human erythropoietin (rHuEPO...

...Wolfgang Pronai; Michaela Riegler-Keil; Karl Silberbauer; Felix Stockenhuber Therapy with recombinant human erythropoietin (rhEPO) has become most valuable for the treatment of renal anemia in patients with various chronic renal diseases. For the first time this study presents data showing...

...Ross R. Bailey; Brett I. Shand; Robert J. Walker A 33-year-old man with dystrophia myotonica presented with erythrocytosis and an increased plasma erythropoietin concentration. Investigations showed a horseshoe kidney, one moiety of which was grossly hydronephrotic. Fluid aspirated from the latter...

...Miriam Wald; Abraham Gutnisky; Enri Borda; Leonor Sterin-Borda The results of the studies reported here demonstrate the cardiac non-haematopoietic effect of erythropoietin, providing a new physiological function of the hormone. We demonstrate that myocardium from rat with chronic renal failure (CRF...

... on chronic ambulatory peritoneal dialysis (CAPD), were treated intravenously with this preparation in a dose of 100 mg elemental iron twice monthly. There were five groups. Group 1:41 HD patients who were receiving erythropoietin (EPO) for at least 6 months prior to the addition of IV Fe. In this group, when...

...Yung-Hsiung Lai; Jer-Chia Tsai; Hung-Chun Chen; Jinn-Yuh Guh; Shang-Jyh Hwang; Juei-Hsiung Tsai The effects of recombinant human erythropoietin (rHuEPO) treatment on parathyroid function in patients on maintenance hemodialysis (HD) with secondary hyperparathyroidism (HPT) is poorly understood. We...

...Pablo Ureña; Lynda Bererhi; Sami Houhou; François Bournerias; Kai-Uwe Eckhardt; Armin Kurtz; Tilman B. Drüeke Endogenous erythropoietin (EPO) secretion can still be modulated in patients with end-stage renal failure but only in response to strong stimuli. Thus even anephric dialysis patients...

..., erythropoietin (EPO) may also have immunomodulating properties. The aim of this study was to examine the effect of EPO on lectin-induced T-lymphocyte transformation in uremic patients, as part of its effect on the immune response. Sixteen HD patients and 20 age- and sex-matched healthy controls were compared...